Alect2 amyloidosis: primum non nocere (first, do no harm)
- PMID: 25079018
- DOI: 10.1038/ki.2014.45
Alect2 amyloidosis: primum non nocere (first, do no harm)
Abstract
Said et al. and Larsen et al. present the clinical, morphologic, and genetic features of a recently described amyloidosis, derived from leukocyte chemotactic factor 2 (Alect2), which is beginning to be recognized as an important cause of end-stage renal disease in Hispanics. While the etiology of Alect2 is unknown, and there is currently no effective treatment, it is important to avoid misdiagnosing it as the more common AL, and applying harmful treatment in consequence.
Comment on
-
Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis.Kidney Int. 2014 Aug;86(2):370-7. doi: 10.1038/ki.2013.558. Epub 2014 Jan 22. Kidney Int. 2014. PMID: 24451324
-
Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis.Kidney Int. 2014 Aug;86(2):378-82. doi: 10.1038/ki.2014.11. Epub 2014 Feb 12. Kidney Int. 2014. PMID: 24522497
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous